Do mutator mutations fuel tumorigenesis?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The mutator phenotype hypothesis proposes that the mutation rate of normal cells is insufficient to account for the large number of mutations found in human cancers. Consequently, human tumors exhibit an elevated mutation rate that increases the likelihood of a tumor acquiring advantageous mutations. The hypothesis predicts that tumors are composed of cells harboring hundreds of thousands of mutations, as opposed to a small number of specific driver mutations, and that malignant cells within a tumor therefore constitute a highly heterogeneous population. As a result, drugs targeting specific mutated driver genes or even pathways of mutated driver genes will have only limited anticancer potential. In addition, because the tumor is composed of such a diverse cell population, tumor cells harboring drug-resistant mutations will exist prior to the administration of any chemotherapeutic agent. We present recent evidence in support of the mutator phenotype hypothesis, major arguments against this concept, and discuss the clinical consequences of tumor evolution fueled by an elevated mutation rate. We also consider the therapeutic possibility of altering the rate of mutation accumulation. Most significantly, we contend that there is a need to fundamentally reconsider current approaches to personalized cancer therapy. We propose that targeting cellular pathways that alter the rate of mutation accumulation in tumors will ultimately prove more effective than attempting to identify and target mutant driver genes or driver pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Defective repair replication of DNA in xeroderma pigmentosum
CLEAVER, J. E. (1968) · Nature · doi:10.1038/218652a0 · Cited by 1,729
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
A comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696 · cited 1×
“Whole genome sequencing has also uncovered a process of genome shattering and reassembly that has been termed chromothripsis [44].”
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378 · cited 1×
“Furthermore, it is generally assumed that some cancers arise from mutated stem cells; however, we currently lack extensive information on mutation frequency or rates in human stem cells and in cancer stem cells [58].”
Bohr, V (1985) · Cell · doi:10.1016/0092-8674(85)90150-3 · Cited by 1,237 · cited 1×
“Subsequently, it has been shown that individuals with this disease carry defects in genes which encode proteins involved in nucleotide excision repair [27, 28] and that engineered mutations in the murine homologs of these genes result in an increase in cancer incidence upon exposure to DNA-damaging agents (reviewed in…”
Kunkel, T. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400006200 · Cited by 754 · cited 1×
“nucleotides, a multistep process has evolved, catalyzed by multiple components with a variety of mechanisms for removing mistakes [22, 23].”
Cited by
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
DNA repair, genome stability and cancer: a historical perspective
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.4 · Cited by 774
Hypermutation in human cancer genomes: footprints and mechanisms
Roberts, S. A., & Gordenin, D. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3816 · Cited by 405
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo
Kiraly, O., Gong, G., Olipitz, W., Muthupalani, S., & Engelward, B. P. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004901 · Cited by 169
“While in some cases cancer cells are hypermutable [13], many transformed cells have a normal mutation rate [12], making exposureinduced mutations highly relevant.”
Background
Metadata
- Authors
- Fox, E. J., Prindle, M. J., & Loeb, L. A.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2013-04-17
- Volume
- 32
- Issue
- 3-4
- Pages
- 353-361
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2023570941
- Cited by
- 99
- References
- 13
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do mutator mutations fuel tumorigenesis? https://app.cochat.ai/papers/10.1007/s10555-013-9426-8
- The paper
- Fox, E. J., Prindle, M. J., & Loeb, L. A. (2013). Do mutator mutations fuel tumorigenesis? Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-013-9426-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.